Business
Invivyd Reports Preliminary Fourth Quarter 2025 Revenue and Recent Business Highlights
Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarterPreliminary ending 2025 cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted b
About this update from Invivyd, Inc.
[{"type":"image","alt":"Invivyd","displaySize":"","headline":null,"caption":"Invivyd","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/4a4d9d450de79e16fc0a485fff104ca6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MyR5b2vdhRgALtKrzLKLAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4a4d9d450de79e16fc0a485fff104ca6","width":300,"height":44}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Preliminary Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter","length":155,"tagName":"p"}]},{"val":[{"type":"text","content":"Preliminary ending 2025 cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025","length":138,"tagName":"p"}]},{"val":[{"type":"text","content":"Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025","length":229,"tagName":"p"}]},{"val":[{"type":"text","content":"Potential best-in-class RSV antibody VBY329 nominated for preclinical development","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"Preclinical measles mAb candidate selection targeted for 1H 2026 for treatment and prevention of measles","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Further updates to be provided in conjunction with Form 10-K filing and upcoming ordinary quarterly reporting","length":109,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":816,"olType":false},{"type":"text","content":"NEW HAVEN, Conn., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced preliminary fourth quarter (Q4) revenue and recent business highlights.","length":168,"tagName":"p"},{"type":"text","content":"“We are pleased by strong top-line revenue growth of PEMGARDA® (pemivibart), which we believe is attributable to our commercial execution and the fundamental appeal of monoclonal antibody prophylaxis even in the face of declining COVID vaccination trends. We are actively preparing for the potential commercial launch of VYD2311, an accessibl...